Coherus Oncology, Inc. Common Stock

CHRS stock price research starts with the latest verified quote and recent price history. The figures below are the current data available to US Market AI; unavailable values are left blank rather than estimated.

Coherus Oncology, Inc. Common Stock (CHRS) Stock Price Today

CHRS is trading at $1.26, with a daily move of -3.08% based on the latest quote. Intraday context should be read together with volume, recent price history and the technical indicators below.

Coherus Oncology, Inc. Common Stock (CHRS) Recent Stock Price Performance

The price chart above provides the recent closing-price history used by the research page. This section intentionally separates live price data from forecasts and model estimates.

AI analysis will appear here after a verified research article is published for CHRS. Until then, the page presents the underlying market, technical and fundamental data without inventing commentary.

Current Market Position

A quantitative forecast is not currently available for CHRS.

Key Risks and Research Signals

Readers should consider valuation, earnings, revenue growth, leverage, volatility, sector conditions and company-specific news together. The risk section below keeps these factors separate so the research is easier to review.

No current quantitative forecast is available for CHRS.

Coherus Oncology, Inc. Common Stock (CHRS) Stock Price Prediction Next 7 Days

Use the 7D model row when available. It represents a short-horizon quantitative estimate and should not be presented as a certain future price.

Coherus Oncology, Inc. Common Stock (CHRS) Stock Price Prediction Next 30 Days

Use the 30D model row when available. A longer horizon carries additional uncertainty because new market and company information can change the inputs.

Coherus Oncology, Inc. Common Stock (CHRS) Stock Forecast This Week & This Month

Weekly and monthly search queries are mapped to the corresponding short-horizon model outputs. US Market AI does not create a separate number when a validated model value is unavailable.

The US Market AI price target section refers only to available quantitative estimates. It is not analyst consensus and should not be treated as a guaranteed fair value.

Technical analysis uses the latest stored indicator snapshot. RSI, MACD, moving averages, ATR, ADX, volatility and support/resistance are shown separately so readers can inspect the underlying numbers.

Coherus Oncology, Inc. Common Stock (CHRS) RSI, MACD & Moving Average Analysis

RSI helps describe momentum, MACD helps describe trend/momentum relationships, and the 20-, 50- and 200-period averages provide trend context. The actual values above should be used instead of generic buy or sell claims.

Coherus Oncology, Inc. Common Stock (CHRS) Support & Resistance Levels

When support and resistance values are available, they provide reference levels for technical research. They are not guarantees that price will stop or reverse at those levels.

The fundamentals snapshot brings revenue, profit, free cash flow, EPS, EPS growth, ROE and leverage into one place. Missing fields remain marked as unavailable.

Coherus Oncology, Inc. Common Stock (CHRS) Revenue & Revenue Growth

Revenue and revenue growth help describe the scale and direction of the business. Use the verified figures above when available; no missing growth rate is estimated.

Coherus Oncology, Inc. Common Stock (CHRS) EPS, Free Cash Flow & ROE

EPS, free cash flow and return on equity provide additional profitability and capital-efficiency context. Each metric should be interpreted with the company's industry and reporting period in mind.

Valuation data is presented from the available fundamentals snapshot. PE, forward PE, PEG, price-to-sales, price-to-book, enterprise value and market cap should be compared with the appropriate reporting period and sector context.

Coherus Oncology, Inc. Common Stock (CHRS) Fair Value & Valuation

US Market AI does not label a missing fair-value estimate as a fact. If a validated valuation model is connected later, its methodology and assumptions can be displayed here.

Coherus Oncology, Inc. Common Stock (CHRS) Earnings Date & Results

The earnings table shows stored earnings dates and EPS estimates/actuals when available. Always verify the company's official investor-relations release for the latest filing or announcement.

Coherus Oncology, Inc. Common Stock (CHRS) Earnings Forecast

Earnings forecasts are shown only when verified earnings data is available. The stock-price prediction model is separate from an earnings consensus estimate.

Coherus Oncology, Inc. Common Stock (CHRS) Dividend & Dividend Yield

Dividend yield, amount, ex-dividend date and payment date are not inferred when the dividend feed is unavailable. A future dividend data connector can populate this section.

Coherus Oncology, Inc. Common Stock is covered here using structured company metadata. The page separates company facts from forecasts so readers can distinguish what the company is from what a model estimates about its stock.

Long-term search intent is covered with separate year-specific headings so each forecast topic is clear to readers and search engines. US Market AI will show a numerical value only when a dedicated validated long-horizon model supplies it; short-term predictions are not extrapolated into distant years.

Coherus Oncology, Inc. Common Stock (CHRS) Stock Price Prediction 2026

For Coherus Oncology, Inc. Common Stock (CHRS) stock price prediction 2026, a dedicated 2026 long-horizon model is required. The current page does not convert a short-term prediction into a 2026 target.

Coherus Oncology, Inc. Common Stock (CHRS) Stock Price Prediction 2027

For Coherus Oncology, Inc. Common Stock (CHRS) stock price prediction 2027, US Market AI will display a numerical estimate only when the dedicated 2027 model is validated.

Coherus Oncology, Inc. Common Stock (CHRS) Stock Price Prediction 2030

For Coherus Oncology, Inc. Common Stock (CHRS) stock price prediction 2030, a dedicated long-range model is needed. The 7D, 30D or 90D model outputs are not extrapolated into 2030.

Coherus Oncology, Inc. Common Stock (CHRS) Stock Price Prediction 2035

For Coherus Oncology, Inc. Common Stock (CHRS) stock price prediction 2035, the page will use a dedicated validated long-horizon model when available rather than inventing a distant price target.

Coherus Oncology, Inc. Common Stock (CHRS) Stock Price Prediction 2040

For Coherus Oncology, Inc. Common Stock (CHRS) stock price prediction 2040, any future numerical estimate must come from a dedicated long-range model with documented methodology.

Coherus Oncology, Inc. Common Stock (CHRS) Stock Price Prediction 2050

For Coherus Oncology, Inc. Common Stock (CHRS) stock price prediction 2050, US Market AI will not extrapolate short-term data into a distant year. A validated 2050 model is required before publishing a numerical forecast.

Prediction history is kept separate from current forecasts. This lets readers compare matured predictions with later actual prices instead of treating an unevaluated forecast as an accuracy claim.

Stock research should consider valuation risk, earnings risk, revenue-growth risk, market risk, sector risk, volatility and company-specific events. These are research categories, not predictions that a specific risk will occur.

The latest ticker-linked news is shown below. Headlines and sentiment are kept separate from the quantitative forecast so a news item is not mistaken for a model prediction.